Close Menu

NEW YORK – Evonetix announced Monday a partnership with Belgium-based nanoelectronics firm Imec to increase the scale of production of Evonetix's silicon chips for use in DNA synthesis.

Under the agreement, the firms will work together to scale up manufacturing of Evonetix's microelectromechanical systems-based chips on 8-inch silicon wafers.

"With the support of Imec, a world-renowned leader in microchip technology, we will be able to optimize our highly parallel desktop platform for commercial supply," Evonetix CTO Matthew Hayes said in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.